Accès gratuit
Numéro
Méd. Intensive Réa.
Volume 26, Numéro 1, Janvier 2017
Respiratoire
Page(s) 48 - 55
Section Mise au point / Update
DOI https://doi.org/10.1007/s13546-017-1254-8
Publié en ligne 6 janvier 2017
  • Almirall J, Bolíbar I, Vidal J, Sauca G, Coll P, Niklasson B, Bartolomé M, Balanzó X, (2000) Epidemiology of community-acquired pneumonia in adults: a population-based study. Eur Resp J 15: 757–763 [CrossRef] [Google Scholar]
  • Ewig S, Birkner N, Strauss R, Schaefer E, Pauletzki J, Bischoff H, Schraeder P, Welte T, Hoeffken G, (2009) New perspectives on community-acquired pneumonia in 388,406 patients. Results from a nationwide mandatory performance measurement program in healthcare quality. Thorax 64: 1062–1069 [CrossRef] [PubMed] [Google Scholar]
  • Restrepo M, Jorgensen, JH, Mortensen EM, Anzueto A, (2001) Severe community-acquired pneumonia: current outcomes, epidemiology, etiology and therapy. Curr Opin Infect Dis 14: 703–709 [CrossRef] [PubMed] [Google Scholar]
  • National Heart, Lung, and Blood Institute. Morbidity and mortality: 2012 chart book on cardiovascular, lung, and blood diseases. Bethesda, Maryland: US Department of Health and Human Services. Public Health Service. National Institutes of Health; 2012 www.nhlbi.nih.gov/resources/docs/2012_ChartBook.pdf Accessed October 30, 2016. [Google Scholar]
  • Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R, (1998) The cost of treating community-acquired pneumonia. Clin Ther 20: 820–837 [CrossRef] [PubMed] [Google Scholar]
  • Blum CA, Nigro N, Briel M, Schuetz P, Ullmer E, Suter-Widmer I, Winzeler B, Bingisser R, Elsaesser H, Drozdov D, Arici B, Urwyler SA, Refardt J, Tarr P, Wirz S, Thomann R, Baumgartner C, Duplain H, Burki D, Zimmerli W, Rodondi N, Mueller B, Christ-Crain M, (2015) Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomized, placebo-controlled trial. Lancet 385: 1511–1518 [CrossRef] [PubMed] [Google Scholar]
  • Torres A, Sibila O, Ferrer M, Polverino E, Menendez R, Mensa J, Gabarrus A, Sellares J, Restrepo MI, Anzueto A, Niederman MS, Agusti C, (2015) Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA 313: 677–686 [CrossRef] [PubMed] [Google Scholar]
  • Angus DC, Marrie TJ, Obrosky DS, Clermont G, Dremsizov TT, Coley C, Fine MJ, Singer DE, Kapoor WN, (2002) Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society diagnostic criteria. Am J Respir Crit Care Med 166: 717–723 [CrossRef] [PubMed] [Google Scholar]
  • Leroy O, Santré C, Beuscart C, Georges H, Guery B, Jacquier JM, Beaucaire G, (1995) A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit. Intensive Care Med 21: 24–31 [CrossRef] [PubMed] [Google Scholar]
  • Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN, (1997) A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 336: 243–250 [CrossRef] [PubMed] [Google Scholar]
  • Lim WS, Van Der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, Lewis SA, Macfarlane JT, (2003) Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 58: 377–382 [CrossRef] [PubMed] [Google Scholar]
  • Wunderink RG, Laterre PF, Francois B, Perrotin D, Artigas A, Vidal LO, Lobo SM, Juan JS, Hwang SC, Dugernier T, LaRosa S, Wittebole X, Dhainaut JF, Doig C, Mendelson MH, Zwingelstein C, Su G, Opal S, CAPTIVATE Trial Group, (2011) Recombinant Tissue Factor Pathway Inhibitor in severe community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 183: 1561–1568 [CrossRef] [PubMed] [Google Scholar]
  • Chalmers JD, (2016) Corticosteroids for community-acquired pneumonia: a critical view of the evidence. Eur Respir J 48:984–986 [CrossRef] [PubMed] [Google Scholar]
  • Coutinho AE, Chapman KE, (2011) The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocr 335: 2–13 [CrossRef] [Google Scholar]
  • Ramamoothy S, Cidlowski J, (2016). Corticosteroids: mechanisms of action in health and disease. Rheum Dis Clin North Am 42: 15–31 [CrossRef] [PubMed] [Google Scholar]
  • Prigent H, Maxime V, Annane D, (2004) Corticotherapy in sepsis. Crit Care 8: 112–119 [CrossRef] [Google Scholar]
  • Wagner HN Jr, Bennett IL Jr, Lasagna L, Cluff LE, Rosenthal MB, Mirick GS, (1956) The effect of hydrocortisone upon the course of pneumococcal pneumonia treated with penicillin. Bull Johns Hopkins Hosp 98: 197–215 [PubMed] [Google Scholar]
  • McHardy VU, Schonell ME, (1972) Ampicillin dosage and use of prednisolone in treatment of pneumonia: co-operative controlled trial. BMJ 4: 569–573 [CrossRef] [Google Scholar]
  • Marik P, Kraus P, Sribante J, Havlik I, Lipman J, Johnson DW, (1993) Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia: a randomized controlled study. Chest 104: 389–392 [CrossRef] [PubMed] [Google Scholar]
  • Confalonieri M, Urbino R, Potena A, Piattella M, Parigi P, Puccio G, Della Porta R, Giorgio C, Blasi F, Umberger R, Meduri GU, (2005) Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 171: 242–248 [CrossRef] [PubMed] [Google Scholar]
  • El-Ghamrawy AH, Shokeir MH, Esmat AA, (2006) Effects of low-dose hydrocortisone in ICU patients with severe community-acquired pneumonia. Egypt J Chest Dis Tuberc 55: 91–99 [Google Scholar]
  • Mikami K, Suzuki M, Kitagawa H, Kawakami M, Hirota N, Yamaguchi H, Narumoto O, Kichikawa Y, Kawai M, Tashimo H, Arai H, Horiuchi T, Sakamoto Y, (2007) Efficacy of corticosteroids in the treatment of community-acquired pneumonia requiring hospitalization. Lung 185: 249–255 [CrossRef] [PubMed] [Google Scholar]
  • Snijders D, Daniels JM, de Graaff CS, van der Werf TS, Boersma WG, (2010) Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blind clinical trial. Am J Respir Crit Care Med 181: 975–982 [CrossRef] [PubMed] [Google Scholar]
  • Meijvis SC, Hardeman H, Remmelts HH, Heijligenberg R, Rijkers GT, van Velzen-Blad H, Voorn GP, van de Garde EM, Endeman H, Grutters JC, Bos WJ, Biesma DH, (2011) Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomized, double-blinded, placebo-controlled trial. Lancet 377: 2023–2030 [CrossRef] [PubMed] [Google Scholar]
  • Sabry NA, Omar EE, (2011) Corticosteroids and ICU course of community acquired pneumonia in Egyptian settings. Pharmacol Pharm 2: 73–81 [CrossRef] [Google Scholar]
  • Fernández-Serrano S, Dorca J, Garcia-Vidal C, Fernández-Sabé N, Carratalà J, Fernández-Agüera A, Corominas M, Padrones S, Gudiol F, Manresa F, (2011) Effect of corticosteroids on the clinical course of community-acquired pneumonia: a randomized controlled trial. Crit Care 15: 1–9 [CrossRef] [Google Scholar]
  • Nafae RM, Ragab MI, Amany FM, Rashed SB, (2013) Adjuvant role of corticosteroids in the treatment of community-acquired pneumonia. Egypt J Chest Dis Tuberc 62: 439–445 [CrossRef] [Google Scholar]
  • Wirz SA, Blum CA, Schuetz P, Albrich WC, Noppen C, Mueller B, Christ-Crain M, Tarr PE, (2016) Pathogen and antibiotic-specific effects of prednisolone in community-acquired pneumonia. Eur Respir J 48: 1150–1159 [CrossRef] [PubMed] [Google Scholar]
  • Ewig S, Ruiz M, Mensa J, Marcos MA, Martinez JA, Arancibia F, Niederman MS, Torres A, (1998) Severe community-acquired pneumonia: assessment of severity criteria. Am J Respir Crit Care Med 158: 1102–1108 [CrossRef] [PubMed] [Google Scholar]
  • Nie W, Zhang Y, Cheng J, Xiu Q, (2012) Corticosteroids in the treatment of community-acquired pneumonia in adults: a meta-analysis. Plos One 7: e47926 [CrossRef] [Google Scholar]
  • Cheng M, Pan ZY, Yang J, Gao YD, (2014) Corticosteroids therapy for severe community-acquired pneumonia: a meta-analysis. Resp Care 59: 557–563 [CrossRef] [Google Scholar]
  • Marti C, Grosgurin O, Harbarth S, Combescure C, Abbas M, Rutschmann O, Perrier A, Garin N, (2015) Adjunctive corticotherapy for community-acquired pneumonia: a systematic review and meta-analysis. PLoS One 10: e0144032 [CrossRef] [Google Scholar]
  • Horita N, Otsuka T, Haranaga S, Namkoong H, Miki M, Miyashita N, Higa F, Takahashi H, Yoshida M, Kohno S, Kaneko T, (2015) Adjunctive systemic corticosteroids for hospitalized community-acquired pneumonia: systematic review and meta-analysis 2015 update. Sci Rep 5:14061 [CrossRef] [PubMed] [Google Scholar]
  • Chen LP, Chen JH, Chen Y, Wu C, Yang XH, (2015) Efficacy and safety of glucocorticoids in the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials. World J Emerg Med 6: 172–178 [CrossRef] [Google Scholar]
  • Siemieniuk RAC, Meade MO, Alonso-Coello P, Briel M, Evaniew N, Prasad M, Alexander PE, Fei Y, Vandvik PO, Loeb M, Guyatt GH, (2015) Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: a systematic review and meta-analysis. Ann Intern Med 163: 519–528 [CrossRef] [PubMed] [Google Scholar]
  • Wan YD, Sun TW, Liu ZQ, Zhang SG, Wang LX, Kan QC, (2016) Efficacy and safety of corticosteroids for community-acquired pneumonia: a systematic review and meta-analysis. Chest 149: 209–219 [CrossRef] [PubMed] [Google Scholar]
  • Feldman C, Anderson R, (2016) Corticosteroids in the adjunctive therapy of community-acquired pneumonia: an appraisal of recent meta-analyses of clinical trials. J Thorac Dis 8: E162–171 [CrossRef] [PubMed] [Google Scholar]
  • Tagami T, Matsui H, Horiguchi H, Fushimi K, Yasunaga H, (2014) Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients. Eur Respir J 45: 463–472 [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.